Comparative Long-term Effects of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Real-life Study with Five-year Follow-up.

Thorac Res Pract · 2025 · PMC12572913 · PMID 40569699

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

21 For pirfenidone, the CAPACITY and ASCEND trials reported a reduction in exacerbation rates among patients treated with pirfenidone, but these reductions did not reach statistical significance. 7 , 8 A meta-analysis by Petnak et al. 22 compared the risk of acute exacerbations between IPF patients receiving antifibrotic therapy and those who did not.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.